Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012318 | 0.86 | CYP1A2 (0.53) | PTGS1CYP1A2MAPK1CYP2C19RAB9A | |
| SCHEMBL1011476 | 0.86 | CYP1A2 (0.57) | PTGS1CYP1A2MAPK1CYP2C19RAB9A | |
| SCHEMBL1013645 | 0.84 | PTGS2 (0.55) | PTGS1RAB9ASMN1; SMN2PTGS2MEN1 | |
| SCHEMBL1012636 | 0.83 | CYP1A2 (0.54) | PTGS1CYP1A2MAPK1CYP2C19RAB9A | |
| SCHEMBL1013244 | 0.83 | CYP2C9 (0.57) | PTGS1CYP1A2CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL13014987 | 0.82 | PTGS2 (0.49) | PTGS1CYP1A2MAPK1CYP2C19ALDH1A1 | |
| SCHEMBL1013431 | 0.82 | ALDH1A1 (0.65) | PTGS1CYP1A2MAPK1CYP2C19RAB9A | |
| SCHEMBL13860427 | 0.82 | CYP1A2 (0.49) | PTGS1CYP1A2MAPK1CYP2C19RAB9A | |
| SCHEMBL14659672 | 0.82 | TRPV1 (0.51) | SMN1; SMN2PTGS2KLKB1 | |
| SCHEMBL1264553 | 0.82 | CYP1A2 (0.61) | PTGS1CYP1A2MAPK1CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025002289-A1 | PYRAZOLOHETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湖南九典制药股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-119219638-A | Pyrazoloheteroaryl compound and preparation method and application thereof | 湖南九典制药股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119060018-A | N, N-diaryl urea derivative and application thereof | 杭州百新生物医药科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| CN-101553232-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| CN-101516379-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-08-26 | — | — | CN | disclosed |
| EP-2063896-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008033999-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | PTGS1 157/4885CYP1A2 2955/4885MAPK1 128/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | PTGS1 1269/4885CYP1A2 3232/4885MAPK1 126/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | PTGS1 157/4885CYP1A2 2955/4885MAPK1 128/4885 |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | NR3C1, NR3C2, GRK3 | PTGS1 657/4885CYP1A2 3730/4885MAPK1 1325/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | PTGS1 1047/4885CYP1A2 3849/4885MAPK1 93/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | PTGS1 157/4885CYP1A2 2955/4885MAPK1 128/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | PTGS1 1047/4885CYP1A2 3849/4885MAPK1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.